Satellos Bioscience (MSCL) Corporate presentation summary

Company and pipeline

• Oral, once-daily forazapadin (SAT-3247), an AAK1 inhibitor, is designed to restore muscle stem-cell polarity and regeneration; clinical programs target DMD and FSHD.

• BASECAMP is a double-blind, placebo-controlled Phase 2 study in 53 ambulatory boys aged 7–9; enrollment is complete across 17 sites in 7 countries.

• TRAILHEAD is an open-label Phase 2 study in adults with DMD; TRAVERSE is planned as a Phase 2 study in adults with FSHD1 or FSHD2.

Rationale and mechanism

• DMD muscle stem cells fail to produce enough progenitor cells to repair damage; regenerative capacity falls sharply at ages 5–9, as muscle loss begins to exceed gains.

• Dystrophin normally regulates muscle stem-cell polarity and asymmetric division; forazapadin inhibits AAK1 to restore the repair signal without relying on dystrophin expression.

• FSHD-related DUX4 expression represses PAX7 and impairs stem-cell function; forazapadin is designed to act downstream of the genetic defect, independent of DUX4.

• The presentation cites no approved therapies that regenerate muscle in DMD or FSHD; FSHD has no disease-modifying options, while steroids have toxic side effects and genetic therapies reach narrow subsets.

Clinical evidence

• In a Phase 1b study, 5 adults with DMD received 60 mg daily on weekdays for 4 weeks; forazapadin was well tolerated, with a favorable safety profile and early functional signals.

• Phase 1b showed near-doubling of handgrip strength; proteomic biomarker changes were detected after 15 days, and grip gains correlated with drug exposure and baseline creatinine.

• In a 6-month TRAILHEAD update from 4 adults, MRI muscle fat fraction fell in all participants, total effort rose ~34%, and handgrip gains from the earlier study were maintained; no serious TEAEs were reported.

• In the canine DMD study, flexion tetanic torque increased up to 2x at 2 months and 4x at 4 months; in an FSHD mouse model, force was 19% above vehicle at week 8 and 29% at week 12.